OPTUNE® TREATMENT FOR
GLIOBLASTOMA (GBM)
Intended for US healthcare professionals only.

Help to prevent and manage dermatologic adverse events (dAEs)

  • The most common adverse event associated with Optune in clinical trials was skin irritation beneath the transducer arrays.1 For this reason, it is important to monitor not only the patient's clinical status, but also his or her scalp health.

    Tips to minimize skin irritation1

    Advise patients to:

    • Change transducer arrays at least twice a week (every 4 days at most)
    • Shift transducer arrays during routine exchanges according to transducer array layout map
      • Place new array 0.75 inches away from the last place it was on the skin to avoid irritation
    • Remove arrays gently by pulling back on the edge of the array, taking a minute to remove each array
    • Avoid placing ceramic discs directly over screws, plates, or scars
    • Notify provider of erythema or irritation
    • Ensure proper ventilation of transducer arrays

    Recommend ventilated, protective wigs or hats in hot weather.1
    Visit Optunedailylife.com for a list of head coverings

  • Tips to help prevent skin irritation and potential infection1

    Advise patients to:

    • Always wash hands prior to application and removal of transducer arrays

      Always wash their hands prior to application and removal of transducer arrays

    • Wash scalp between transducer array exchanges

      Wash their scalp between transducer array exchanges

    • Clean the electric razor per manufacturer’s guidelines after every shave

      Clean the electric razor per manufacturer’s guidelines after every shave

    • Help reduce the risk of skin irritation with proper transducer array placement and shifting

      Help reduce the risk of skin irritation with proper transducer array placement and shifting

    Advise patients to avoid putting ceramic discs or adhesive tape over areas affected by a dAE when placing or exchanging arrays

  • Key risk factors correlated with dAEs1:

    • High doses or recent change in systemic corticosteroids
    • Concurrent administration of chemotherapy, biologics, or targeted therapies
    • Previous skin exposure to ultraviolet or ionizing radiation
    • History of contact dermatitis (eg, from tape adhesive or hydrogel)
    • Excessive sweating from hot, humid weather or occlusive wigs
    • Placement of transducer arrays (ie, ceramic discs) overlying scars or craniotomy hardware
  • Treatment options for dAEs are dependent upon the type and severity of the dAE.1

    Causes and management of common dAEs Causes and management of common dAEs

    Skin irritations seen as a result of treatment with Optune can usually be managed with proper skin care and the use of medications, such as topical corticosteroids and antibiotics, without discontinuing therapy


Download your guide to managing dermatologic adverse events

Your guide to preventing, identifying, and managing dAEs for patients using Optune to help maximize time on therapy

View this PDF

References: 1. Lacouture ME, Davis ME, Elzinga G, et al. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014;41(3 suppl 4):S1-14. 2. Novocure Data on File OPT-147.
3. Jennings DL II, Sumrall AL, Haggstrom DE. Classification of dermatologic adverse events and management strategies in patients receiving therapy with Optune for high grade gliomas. Poster presented at: 2016 Society for NeuroOncology (SNO) Annual Meeting: November 17-20, 2016; Scottsdale, AZ.

Indications For Use

Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).